Rodent studies suggest the
addition of Baraclude
entecavir
to plasmid- and adenoviral vector-based vaccination protocols could help
treat chronic HBV infection. In woodchucks chronically infected with woodchuck
hepatitis virus (WHV), pretreatment with entecavir followed by injection of a
DNA vaccine encoding WHV core antigen led to a more potent antiviral immune
response than either treatment alone. Next steps could include developing an
analogous vaccine candidate for HBV and evaluating it using the same protocol
in combination with entecavir.Bristol-Myers
Squibb Co. markets Baraclude, a cyclopentile
guanosine nucleoside analog, to treat HBV infection.

Access this BioCentury Innovations article Distillery article for your individual use via a permanent link that allows you to read or print the article: $18.
The article link will be posted on the purchase transaction web page, and also emailed to you with your purchase confirmation.

Purchase This Article for Limited One-Time Distribution and Posting to Your Website :

Receive a formatted PDF reprint of this article with rights for limited one-time redistribution and posting to your website: $750. Please allow 24-48 hours for delivery.

Purchase Options

Purchase this article for individual use $18 USDPurchase this article for limited one-time distribution and website posting $750 USD